Kyverna Therapeutics Inc (KYTX)

08:56 AM

Kyverna secures $150 million loan facility to advance autoimmune therapies By Investing.com - Investing.com Australia

08:56 AM

06:37 AM

What the charts say about Kyverna Therapeutics Inc. todayJuly 2025 Patterns & Technical Confirmation Trade Alerts - newser.com

06:37 AM

04:29 AM

Is Kyverna Therapeutics Inc. stock attractive for passive investorsEarnings Trend Report & Daily Growth Stock Tips - newser.com

04:29 AM

04:20 AM

Why Kyverna Therapeutics Inc. stock remains undervaluedQuarterly Earnings Report & Safe Capital Growth Stock Tips - newser.com

04:20 AM

04:16 AM

Is Kyverna Therapeutics Inc. stock vulnerable to regulatory risks2025 Growth vs Value & Real-Time Volume Triggers - newser.com

04:16 AM

03:56 AM

Pattern recognition hints at Kyverna Therapeutics Inc. upside2025 Market Outlook & Verified Short-Term Trading Plans - newser.com

03:56 AM

Nov 03, 2025

Kyverna secures $150 million loan facility to advance autoimmune therapies - Investing.com

Nov 03, 2025

Nov 03, 2025

Kyverna Therapeutics Secures $150 Million Loan Facility - TipRanks

Nov 03, 2025

Nov 03, 2025

Kyverna Therapeutics Secures up to $150 Million in Non-Dilutive Financing from Oxford Finance - The Manila Times

Nov 03, 2025

Nov 03, 2025

[8-K] Kyverna Therapeutics, Inc. Reports Material Event | KYTX SEC FilingForm 8-K - Stock Titan

Nov 03, 2025

Nov 03, 2025

Kyverna (Nasdaq: KYTX) secures up to $150M non-dilutive financing maturing 2030 - Stock Titan

Nov 03, 2025

Nov 03, 2025

Using economic indicators to assess Kyverna Therapeutics Inc. potentialJuly 2025 Catalysts & Weekly Setup with ROI Potential - newser.com

Nov 03, 2025

Nov 03, 2025

How sentiment analysis helps forecast Kyverna Therapeutics Inc.CEO Change & Safe Capital Preservation Plans - newser.com

Nov 03, 2025

Nov 03, 2025

Kyverna Therapeutics Reports Positive Phase 2 Trial Results - MSN

Nov 03, 2025

Nov 03, 2025

Will Kyverna Therapeutics Inc. stock deliver long term returnsMarket Growth Review & Weekly Market Pulse Alerts - newser.com

Nov 03, 2025

Nov 03, 2025

Combining price and volume data for Kyverna Therapeutics Inc.Weekly Trade Summary & Safe Entry Momentum Tips - newser.com

Nov 03, 2025

Nov 03, 2025

Can machine learning forecast Kyverna Therapeutics Inc. recoveryTrade Entry Summary & High Accuracy Trade Alerts - newser.com

Nov 03, 2025

Nov 02, 2025

Is Kyverna Therapeutics Inc. stock a buy before product launchesTrade Analysis Report & Daily Risk Controlled Trade Plans - newser.com

Nov 02, 2025

Oct 31, 2025

Analysts Conflicted on These Healthcare Names: Kyverna Therapeutics, Inc. (KYTX), Disc Medicine (IRON) and Baxter International (BAX) - The Globe and Mail

Oct 31, 2025

Oct 31, 2025

Kyverna Therapeutics (KYTX) Price Target Increased by 16.46% to 23.46 - MSN

Oct 31, 2025

Oct 30, 2025

Kyverna Therapeutics, Inc. (KYTX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK

Oct 30, 2025

Oct 30, 2025

Promising Phase 2 Data and Favorable Safety Profile Drive Buy Rating for Kyverna Therapeutics’ KYV-101 - TipRanks

Oct 30, 2025

Oct 30, 2025

What is HC Wainwright's Estimate for KYTX Q3 Earnings? - MarketBeat

Oct 30, 2025

Oct 30, 2025

Kyverna Therapeutics Advances in Lupus Nephritis Treatment with KYV-101 CAR T-Cell Therapy - MSN

Oct 30, 2025

Oct 30, 2025

Kyverna’s CAR T Therapy Sets 'New Efficacy Standard' in Myasthenia Gravis, De-Risking Phase III Trials - BioSpace

Oct 30, 2025

Oct 29, 2025

Amen at AANEM: Kyverna makes good on MG phase II promise - BioWorld MedTech

Oct 29, 2025

Oct 29, 2025

Kyverna Therapeutics Reports Positive Phase 2/3 Trial Data - TipRanks

Oct 29, 2025

Oct 29, 2025

Kyverna Therapeutics stock surges after positive myasthenia gravis trial data By Investing.com - Investing.com Canada

Oct 29, 2025

Oct 29, 2025

KYTX to host 8:00 a.m. ET call on KYV-101 Phase 2/3 results - Stock Titan

Oct 29, 2025

Oct 29, 2025

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025 - The Manila Times

Oct 29, 2025

Oct 29, 2025

Kyverna Therapeutics Reports Promising Interim Results from Phase 2 Trial of KYV-101 in Generalized Myasthenia Gravis, Setting a New Clinical Standard - Quiver Quantitative

Oct 29, 2025

Oct 29, 2025

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study - TradingView

Oct 29, 2025

Oct 29, 2025

Kyverna Therapeutics announces positive interim phase 2 data from KYSA-6 study of KYV-101 in generalized Myasthenia gravis at AANEM 2025 - MarketScreener

Oct 29, 2025

Oct 29, 2025

Kyverna KYTX shares Phase 2 interim KYV-101 results in gMG update - Stock Titan

Oct 29, 2025

Oct 29, 2025

Kyverna (Nasdaq: KYTX): 100% MG-ADL and QMG response in gMG Phase 2; no ICANS - Stock Titan

Oct 29, 2025

Oct 28, 2025

How strong is Kyverna Therapeutics Inc. stock balance sheet2025 Year in Review & Fast Exit/Entry Strategy Plans - fcp.pa.gov.br

Oct 28, 2025